GSK presents extensive oncology data at ESMO investor update
GSK disclosed Phase III and early‑stage results for several oncology candidates at its ESMO investor briefing. The osteosarcoma trial of ris‑rez showed a median progression‑free survival of 5.5 months versus 1.1 months with chemotherapy, while mo‑rez achieved a 62% objective response rate at the 5.8 mg/kg dose in platinum‑resistant ovarian cancer. Dostarlimab reported a 68% clinical complete response rate in dMMR rectal cancer, and the ROS1‑positive lung cancer drug JIDEYTRO demonstrated a 94% objective response rate in treatment‑naïve patients. GSK also announced recruitment for a Phase III small‑cell lung cancer study and plans to start a first‑line trial before year‑end.
Why it matters
The data suggest strong efficacy across multiple tumor types, which could enhance GSK's oncology pipeline valuation and support future regulatory submissions. The company indicated that the small‑cell lung cancer study will begin before the end of the year, potentially adding a new indication for ris‑rez.
Key facts
- 1In the Phase III osteosarcoma trial, median PFS was 5.5 months with ris‑rez and 1.1 months with chemotherapy. finance.yahoo.com
- 2The same osteosarcoma study reported an objective response rate of 15% for ris‑rez versus 2% for the control arm. finance.yahoo.com
- 3Disease‑control rates were 76% for ris‑rez and 33% for chemotherapy in the osteosarcoma trial. finance.yahoo.com
- 4Mo‑rez achieved a 62% confirmed objective response rate at the selected 5.8 mg/kg dose in platinum‑resistant ovarian cancer. finance.yahoo.com
- 5At that dose, median duration of response was 12.2 months and median progression‑free survival was 11.1 months. finance.yahoo.com
- 6Dostarlimab showed a 68% clinical complete response rate at 12 months in dMMR rectal cancer. finance.yahoo.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.